Mina Sooch resigned as president, CEO and director of Gemphire Therapeutics Inc. due to personal reasons, effective May 23.

Steven Gullans, a board member since April 2016, has been named interim president and CEO until a search for a replacement is completed.

Gullans is a managing director at venture capital firm Excel Venture Management LLC, which owns more than 5% of Gemphire's outstanding common stock.